R&D News | pharmaphorum

News

Keytruda shadows GSK's Jemperli in endometrial cancer

GSK had just two months to celebrate the positive phase 3 result with its checkpoint inhibitor Jemperli as a first-line therapy for endometrial cancer, before Merck &

News

4DMT's Fabry gene therapy on hold, but 'remains active'

4D Molecular Therapeutics (4DMT) has said a trial of its gene therapy for Fabry disease has been placed on a clinical hold by the FDA, a few weeks after it reported three

News

Sanofi drops BTK drug tolebrutinib in myasthenia gravis

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular diso

News

Roche finally drops curtain on AKT drug ipatasertib

In amongst a clutch of discontinued phase 3 programmes in Roche's fourth-quarter results update

News

FDA approves GSK’s oral treatment of dialysis anaemia

The US Food and Drug Administration (FDA) has approved the

News

Evelo hit by SINTAX error in atopic dermatitis trial

Evelo Biosciences' lead drug candidate has failed a midstage trial in atopic dermatitis, wreaking havoc with its share price, but the biotech says it still plans to go ahe

Keytruda shadows GSK's Jemperli in endometrial cancer

4DMT's Fabry gene therapy on hold, but 'remains active'

Sanofi drops BTK drug tolebrutinib in myasthenia gravis

Roche finally drops curtain on AKT drug ipatasertib

FDA approves GSK’s oral treatment of dialysis anaemia

Evelo hit by SINTAX error in atopic dermatitis trial

Pharvaris plans filings for HAE drug after pivotal trial win

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks